FDA Misses Regulatory Deadline for Proposed Ban on Behavioral Electrical Stimulation Devices

The Food and Drug Administration has missed a scheduled deadline to finalize a federal ban on electrical stimulation devices used to modify behaviors in autistic and developmentally disabled individuals. These devices, which deliver high-voltage electric shocks, have been the subject of ongoing scrutiny from international human rights organizations and medical associations. The current regulatory delay has prompted renewed calls from advocacy groups for the agency to fulfill its proposed mandate to prohibit the use of these tools in clinical settings.

The delay in finalizing the ban on electrical stimulation devices highlights a complex intersection between clinical behavioral practices, federal regulatory authority, and human rights advocacy. While the FDA was granted specific congressional authority in 2023 to move forward with a prohibition, the regulatory process has faced significant legal hurdles, including past judicial intervention that overruled previous attempts to outlaw the practice. The continued use of these devices remains a point of contention, with professional medical bodies such as the American Academy of Pediatrics arguing that such methods pose significant risks for physical and psychological trauma rather than providing therapeutic benefits for self-injurious or aggressive behaviors.

From an industry perspective, this development underscores the evolving standards for behavioral modification and the increasing pressure to align domestic mental health practices with international human rights guidelines. Advocacy groups and international bodies, including the United Nations, have characterized the use of electricity for behavior modification as inhumane, placing the burden on regulators to reconcile historical practices with modern ethical expectations. As the FDA navigates the finalization of its rule, the outcome will likely influence future oversight of psychiatric and psychological interventions. The situation reflects a broader trend of increased institutional accountability, as medical facilities face heightened scrutiny regarding the safety and necessity of aversive therapies in the care of vulnerable populations.